Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies

Therapeutic Delivery

Volumn 2, Issue 12, 2011, Pages 1633-1653

  Griffin, B T ^a   O'Driscoll, C M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CYCLOSPORIN A; FORTAVASE; INSULIN; LEUPRORELIN; MURAMYL DIPEPTIDE DERIVATIVE; N ACETYLGLUCOSAMINYL N ACETYLMURAMYL; NONIONIC SURFACTANT; SALCATONIN; SAQUINAVIR; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

CELL METABOLISM; CELL TRANSPORT; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; ENZYMATIC DEGRADATION; FLUIDIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHILICITY; HYDROPHOBICITY; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; LIPOSOMAL DELIVERY; MICROEMULSION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REPRODUCIBILITY; REVIEW; STOMACH ULCER; STRUCTURE ANALYSIS; TIGHT JUNCTION;

EID: 81255198647     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.128     Document Type: Review

References (130)

1. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2(4), 289-295 (2003). (Pubitemid 37361687)
2. Kovarik JM, Mueller EA, Van Bree JB et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation -a multicenter investigation in kidney transplant patients. Transplantation 58(6), 658-663 (1994). (Pubitemid 24317763)
3. Fjellestad-Paulsen A, Hoglund P, Lundin S, Paulsen O. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin. Endocrinol. 38(2), 177-182 (1993). (Pubitemid 23042726)
4. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 20(2-3), 153-214 (2003). (Pubitemid 37237279)
5. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6(3), 231-248 (2007). (Pubitemid 46344627)
6. O'Driscoll CM, Griffin BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility -the potential impact of lipid-based formulations. Adv. Drug Deliv. Rev. 60(6), 617-624 (2008).
7. Banga AK, Chien YW. Systemic delivery of therapeutic peptides and proteins. Int. J. Pharm. 48(1-3), 15-50 (1988).
8. Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21(6), 897-903 (2004). (Pubitemid 38870136)
9. Sarciaux JM, Acar L, Sado PA. Using microemulsion formulations for oral-drug delivery of therapeutic peptides. Int. J. Pharm. 120(2), 127-136 (1995).
10. Wang W. Oral protein drug delivery. J. Drug Target. 4(4), 195-232 (1996). (Pubitemid 26421822)
11. Augustijns PF, Bradshaw TP, Gan LS, Hendren RW, Thakker DR. Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197(2), 360-365 (1993). (Pubitemid 24034579)
12. Ritschel WA. Microemulsions for improved peptide absorption from the gastrointestinal tract. Methods Find. Exp. Clin. Pharmacol. 13(3), 205-220 (1991).
13. Lee VH. Enzymatic barriers to peptide and protein absorption. Crit. Rev. Ther. Drug Carrier Syst. 5(2), 69-97 (1988).
14. Rubas W, Cromwell ME, Shahrokh Z et al. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J. Pharm. Sci. 85(2), 165-169 (1996). (Pubitemid 26059882)
15. Salama NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58(1), 15-28 (2006).
16. Bendayan M, Ziv E, Gingras D, Ben-Sasson R, Bar-On H, Kidron M. Biochemical and morpho-cytochemical evidence for the intestinal absorption of insulin in control and diabetic rats. Comparison between the effectiveness of duodenal and colon mucosa. Diabetologia 37(2), 119-126 (1994). (Pubitemid 24042878)
17. Drewe J, Fricker G, Vonderscher J, Beglinger C. Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether. Br. J. Pharmacol. 108(2), 298-303 (1993). (Pubitemid 23032529)
18. Pauletti GM, Okumu FW, Borchardt RT. Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway. Pharm. Res. 14(2), 164-168 (1997). (Pubitemid 27146358)
19. Conradi RA, Hilgers AR, Ho NF, Burton PS. The influence of peptide structure on transport across Caco-2 cells. II. Peptide bond modification which results in improved permeability. Pharm. Res. 9(3), 435-439 (1992).
20. Bai JP, Amidon GL. Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharm. Res. 9(8), 969-978 (1992).
21. GM Paulettia, S Gangwara, TJ Siahaana, J Aubéd, RT Borchardt. Improvement of oral peptide bioavailability: peptidomimetics and prodrug strategies. Adv. Drug Deliv. Rev. 27(2-3), 235-256 (1997). (Pubitemid 27417875)
22. Alsenz J, Russell-Jones GJ, Westwood S, Levet-Trafit B, De Smidt PC. Oral absorption of peptides through the cobalamin (vitamin B12) pathway in the rat intestine. Pharm. Res. 17(7), 825-832 (2000). (Pubitemid 30666963)
23. Strickley RG. Currently marketed oral lipid based dosage forms:drug products and excipeints. In: Oral Lipid Based Formulations. Hauss DJ (Ed.). Informa Healthcare, London, UK, 1-32 (2007).
24. Porter CJH, Wasan KM, Constantinides P. Lipid-based systems for the enhanced delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev. 60(6), 615-616 (2008).
25. Bhargava HN, Narurkar A, Lieb LM. Using microemulsions for drug delivery. Pharm. Technol. 11, 46-54 (1987).
26. Lindman B, Stibbs P. Molecular diffusion in microemulsions. In; Microemulsions: Structure and Dynamics. Friberg SE, Bothorel P (Eds). CRC Press, FL, USA, 119-152 (1987).
27. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45(1), 89-121 (2000).
28. Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. Self emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int. J. Pharm. 106(1), 15-23 (1994). (Pubitemid 24110060)
29. O'Driscoll CM. Lipid based formulations for intestinal lymphatic delivery. Eur. J. Pharm. Sci. 15(5), 405-415 (2002).
30. Gershanik T, Benita S. Self dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur. J. Pharm. Biopharm. 50(1), 179-188 (2000). (Pubitemid 30326696)
31. Swenson ES, Curtalo WJ. Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Adv. Drug Deliv. Rev. 8, 39-92 (1992).
32. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption -physical and biopharmaceutical aspects. Pharm. Res. 12(11), 1561-1572 (1995). (Pubitemid 26005509)
33. Benet LZ. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol. Pharm. 6(6), 1631-1643 (2009).
34. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 29(3-4), 278-287 (2006). (Pubitemid 44740131)
35. Constantinides PP, Scalart JP, Lancaster C et al. Formulation and intestinal-absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm. Res. 11(10), 1385-1390 (1994). (Pubitemid 24339642)
36. Constantinides PP, Welzel G, Ellens H et al. Water-in-oil microemulsions containing medium-chain fatty acids salts: formulation and intestinal absorption enhancement evaluation. Pharm. Res. 13(2), 210-215 (1996). (Pubitemid 26072140)
37. Constantinides PP, Lancaster CM, Marcello J et al. Enhanced intestinal-absorption of an RGD peptide from water-in-oil microemulsions of different composition and particle-size. J. Control. Release 34(2), 109-116 (1995).
38. Lyons KC, Charman WN, Miller R, Porter CJ. Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion. Int. J. Pharm. 199(1), 17-28 (2000). (Pubitemid 30224501)
39. Yoshiura H, Hashida M, Kamiya N, Goto M. Factors affecting protein release behavior from surfactant-protein complexes under physiological conditions. Int. J. Pharm. 338(1-2), 174-179 (2007). (Pubitemid 46777235)
40. Sek L, Porter CJH, Kaukonen AM, Charman WN. Evaluation of the in vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. J. Pharm. Pharmacol. 54(1), 29-41 (2002). (Pubitemid 34116220)
41. Mullertz A, Larsen A, Holm R, Pedersen ML. Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis. Pharm. Res. 25(12), 2769-2777 (2008).
42. Toorisaka E, Ono H, Arimori K, Kamiya N, Goto M. Hypoglycemic effect of surfactant-coated insulin solubilized in a novel solid-in-oil-in-water (S/O/W) emulsion. Int. J. Pharm. 252(1-2), 271-274 (2003). (Pubitemid 36126637)
43. Toorisaka E, Hashida M, Kamiya N, Ono H, Kokazu Y, Goto M. An enteric-coated dry emulsion formulation for oral insulin delivery. J. Control. Release 107(1), 91-96 (2005). (Pubitemid 41253705)
44. Muller RH, Ruhl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 14(4), 458-462 (1997). (Pubitemid 27205004)
45. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59(6), 478-490 (2007). (Pubitemid 47260710)
46. Morel S, Gasco MR, Cavalli R. Incorporation in lipospheres of [d-Trp-6]Lhrh. Int. J. Pharm. 105(2), R1-R3 (1994).
47. Ugazio E, Cavalli R, Gasco MR. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int. J. Pharm. 241(2), 341-344 (2002). (Pubitemid 34718035)
48. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 6(1), 9-24 (2010).
49. Muller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm. 317(1), 82-89 (2006). (Pubitemid 43866342)
50. Garcia-Fuentes M, Prego C, Torres D, Alonso MJ. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci. 25(1), 133-143 (2005). (Pubitemid 40602203)
51. Zhang N, Ping QN, Huang GH, Xu WF, Cheng YN, Han XZ. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm. 327(1-2), 153-159 (2006). (Pubitemid 44667334)
52. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12(3), 413-420 (1995).
53. Macgregor KJ, Embleton JK, Lacy JE et al. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv. Drug Deliv. Rev. 25(1), 33-46 (1997). (Pubitemid 27107789)
54. Luner PE, Vander Kamp D. Wetting behavior of bile salt-lipid dispersions and dissolution media patterned after intestinal fluids. J. Pharm. Sci. 90(3), 348-359 (2001).
55. Kossena GA, Boyd BJ, Porter CJ, Charman WN. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. J. Pharm. Sci. 92(3), 634-648 (2003). (Pubitemid 36258978)
56. Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs: the potential of oily formulations for drug delivery to the gastro-intestinal tract. Adv. Drug Deliv. Rev. 25(1), 103-128 (1997).
57. Meaney CM, O'Driscoll CM. A comparison of the permeation enhancement potential of simple bile salt and mixed bile salt :fatty acid micellar systems using the Caco-2 cell culture model. Int. J. Pharm. 207(1-2), 21-30 (2000).
58. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 11(Suppl. 2), S93-S98 (2000).
59. Lane ME, O'Driscoll C M, Corrigan OI. Quantitative estimation of the effects of bile salt surfactant systems on insulin stability and permeability in the rat intestine using a mass balance model. J. Pharm. Pharmacol. 57(2), 169-175 (2005). (Pubitemid 40129083)
60. Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery -liposomes versus lipid nanoparticles. Int. J. Nanomedicine 2(4), 595-607 (2007).
61. Anderberg EK, Lindmark T, Artursson P. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm. Res. 10(6), 857-864 (1993). (Pubitemid 23167568)
62. Aungst BJ. Intestinal permeation enhancers. J. Pharm. Sci. 89(4), 429-442 (2000).
63. Morley P. Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opin. Drug Deliv. 2(6), 993-1002 (2005). (Pubitemid 41701199)
64. Swenson ES, Milsen WB, Curtalo WJ. Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharm. Res. 11(8), 1132-1142 (1994). (Pubitemid 24259853)
65. Anderberg EK, Artursson P. Epithelial transport of drugs in cell culture. VIII: Effects of sodium dodecyl sulfate on cell membrane and tight junction permeability in human intestinal epithelial (Caco-2) cells. J. Pharm. Sci. 82(4), 392-398 (1993). (Pubitemid 23150434)
66. Hayashi M, Sakai T, Hasegawa Y et al. Physiological mechanism for enhancement of paracellular drug transport. J. Control. Release 62(1-2), 141-148 (1999). (Pubitemid 29486492)
67. Muranishi S. Absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst. 7(1), 1-33 (1990). (Pubitemid 20355576)
68. Maher S, Leonard TW, Jacobsen J, Brayden DJ. Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv. Drug Deliv. Rev. 61(15), 1427-1449 (2009).
69. Leonard TW, Lynch J, Mckenna MJ, Brayden DJ. Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin. Drug Deliv. 3(5), 685-692 (2006). (Pubitemid 44383494)
70. Leone-Bay A, Ho KK, Agarwal R et al. 4-[4-[(2-hydroxybenzoyl)amino] phenyl] butyric acid as a novel oral delivery agent for recombinant human growth hormone. J. Med. Chem. 39(13), 2571-2578 (1996). (Pubitemid 26199147)
71. Milstein SJ, Leipold H, Sarubbi D et al. Partially unfolded proteins efficiently penetrate cell membranes -implications for oral drug delivery. J. Control. Release 53(1-3), 259-267 (1998). (Pubitemid 28218708)
72. Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr. Drug Deliv. 2(2), 191-197 (2005). (Pubitemid 40488628)
73. Kidron M, Dinh S, Menachem Y et al. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet. Med. 21(4), 354-357 (2004). (Pubitemid 38519671)
74. Leone-Bay A, Sato M, Paton D et al. Oral delivery of biologically active parathyroid hormone. Pharm. Res. 18(7), 964-970 (2001). (Pubitemid 32799941)
75. Karsdal MA, Henriksen K, Bay-Jensen AC et al. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J. Clin. Pharmacol. 51(4), 460-471 (2011).
76. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome-P450 3a and p-glycoprotein -implications for drug-delivery and activity in cancer-chemotherapy. Mol. Carcinog. 13(3), 129-134 (1995).
77. Burton PS, Conradi RA, Hilgers AR, Ho NF. Evidence for a polarized efflux system for peptides in the apical membrane of Caco-2 cells. Biochem. Biophys. Res. Commun. 190(3), 760-766 (1993). (Pubitemid 23207830)
78. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm. 277(1-2), 3-9 (2004). (Pubitemid 38670415)
79. Wagner D, Spahn-Langguth H, Hanafy A, Koggel A, Langguth P. Intestinal drug efflux: formulation and food effects. Adv. Drug Deliv. Rev. 50(Suppl. 1), S13-S31 (2001). (Pubitemid 32905353)
80. Woodcock DM, Jefferson S, Linsenmeyer ME et al. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 50(14), 4199-4203 (1990). (Pubitemid 20225651)
81. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. Impact of excipients on the absorption of P glycoprotein substrates in vitro and in vivo. Int. J. Pharm. 278(1), 119-131 (2004). (Pubitemid 38670443)
82. Nerurkar MM, Burton PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13(4), 528-534 (1996). (Pubitemid 26119054)
83. Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res. 16(10), 1550-1556 (1999). (Pubitemid 29510551)
84. Yu L, Bridgers A, Polli J et al. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm. Res. 16(12), 1812-1817 (1999). (Pubitemid 30040695)
85. Linton KJ, Rosenberg MF, Kerr ID, Higgins CF. Structure of ABC transporters. In: ABC Proteins: from Bacteria to Man (1st Edition). Holland IB, Cole SPC, Kuchler K, Higgins CF (Eds). Academic Press, London, UK, 65-80 (2003).
86. Rege BD, Kao JP, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 16(4-5), 237-246 (2002).
87. Bogman K, Zysset Y, Degen L et al. P-glycoprotein and surfactants: effect on intestinal talinolol absorption. Clin. Pharmacol. Ther. 77(1), 24-32 (2005). (Pubitemid 40075386)
88. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int. J. Pharm. 278(1), 119-131 (2004). (Pubitemid 38670443)
89. Konishi T, Satsu H, Hatsugai Y et al. A bitter melon extract inhibits the P-glycoprotein activity in intestinal Caco-2 cells: monoglyceride as an active compound. Biofactors 22(1-4), 71-74 (2004).
90. Lo YL, Huang JD. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem. Pharmacol. 59(6), 665-672 (2000).
91. Ingels F, Deferme S, Destexhe E, Oth M, Van Den Mooter G, Augustijns P. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. Int. J. Pharm. 232(1-2), 183-192 (2002). (Pubitemid 34076764)
92. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22(1), 11-23 (2005). (Pubitemid 40558141)
93. Custodio JM, Wu C-Y, Benet LZ. Predicting drug disposition, absorption/elimination/ transporter interplay and the role of food on drug absorption. Adv. Drug Deliv. Rev. 60(6), 717-733 (2008).
94. O'Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur. J. Pharm. Sci. 15(5), 405-415 (2002).
95. O'Driscoll CM. Anatomy and physiology of the lymphatics. In: Lymphatic Transport of Drugs. Charman WN, Stella VJ (Eds). CRC Press, FL, USA, 1-35 (1992).
96. Sinko PJ, Lee YH, Makhey V et al. Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT). Pharm. Res. 16(4), 527-533 (1999). (Pubitemid 29191297)
97. O'Driscoll C. intestinal lymphatic targeting of drugs. STP Pharm. Sci. 13(1), 17-25 (2003).
98. Takada K, Shibata N, Yoshimura H et al. Promotion of the selective lymphatic delivery of cyclosporin A by lipid-surfactant mixed micelles. J. Pharmacobiodyn. 8(4), 320-323 (1985). (Pubitemid 15055791)
99. Griffin BT, O'Driscoll CM. A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model. J. Pharm. Pharmacol. 58(7), 917-925 (2006). (Pubitemid 43967108)
100. Muranishi S, Fujita T, Murakami M, Yamamoto A. Potential for lymphatic targeting of peptides. J. Control. Release 46(1-2), 157-164 (1997). (Pubitemid 27110895)
101. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut associated lymphoid tissues. 1. Orally adminstered biodegradable microspheres target the peyers patches. J. Control. Release 11(1-3), 205-214 (1990). (Pubitemid 20070098)
102. O' Hagan DT, Illum L. Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine. Crit. Rev. Ther. Drug Carrier Syst. 7(1), 35-97 (1990). (Pubitemid 20355577)
103. Tarr BD, Yalkowsky SH. Enhanced intestinal absorption of cyclosporin in rats through the reduction of emulsion droplet size. Pharm. Res. 6(1), 40-43 (1989). (Pubitemid 19060820)
104. Gao ZG, Choi HG, Shin HJ et al. Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A. Int. J. Pharm. 161(1), 75-86 (1998).
105. Mueller EA, Kovarik JM, Van Bree JB, Grevel J, Lucker PW, Kutz K. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm. Res. 11(1), 151-155 (1994). (Pubitemid 24040779)
106. Lin JH. Human immunodeficiency virus protease inhibitors. From drug design to clinical studies. Adv. Drug Deliv. Rev. 27(2-3), 215-233 (1997). (Pubitemid 27417874)
107. Shinomiya M, Shirai K, Saito Y, Yoshida S, Matsuoka N. Effect of new chymotrypsin inhibitor (FK-448) on intestinal absorption of insulin. Lancet 1(8437), 1092-1093 (1985). (Pubitemid 15075521)
108. Khafagy El S, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv. Drug Deliv. Rev. 59(15), 1521-1546 (2007). (Pubitemid 350122777)
109. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today 11(19-20), 905-910 (2006). (Pubitemid 44403178)
110. Kumar TR, Soppimath K, Nachaegari SK. Novel delivery technologies for protein and peptide therapeutics. Curr. Pharm. Biotechnol. 7(4), 261-276 (2006). (Pubitemid 44194386)
111. Clement S, Still JG, Kosutic G, Mcallister RG. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in Type 1 diabetes mellitus: the glucose stabilization effects of HIM2. Diabetes Technol. Ther. 4(4), 459-466 (2002).
112. Sharma G, Wilson K, Van Der Walle CF, Sattar N, Petrie JR, Ravi Kumar MN. Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. Eur. J. Pharm. Biopharm. 76(2), 159-169 (2010).
113. Shao J, Rao SVR, Yajurvedi K. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of protein drugs III. In vivo oral absorption study. Int. J. Pharm. 362(1-2), 16-19 (2008).
114. Shao J, Rao SVR, Agarwal P. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs II. In vitro transport study. Int. J. Pharm. 362(1-2), 10-15 (2008).
115. Fan Y, Li X, Zhou Y et al. Improved intestinal delivery of salmon calcitonin by water-in-oil microemulsions. Int. J. Pharm. 416(1), 323-330 (2011).
116. Zheng JY, Fulu MY. Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion. Int. J. Pharm. 307(2), 209-215 (2006). (Pubitemid 41820416)
117. Celebi N, Turkyilmaz A, Gonul B, Ozogul C. Effects of epidermal growth factor microemulsion formulation on the healing of stress-induced gastric ulcers in rats. J. Control. Release 83(2), 197-210 (2002). (Pubitemid 35279465)
118. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv. Drug Deliv. Rev. 55(4), 519-548 (2003). (Pubitemid 36423302)
119. Watnasirichaikul S, Rades T, Tucker IG, Davies NM. In vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion. J. Pharm. Pharmacol. 54(4), 473-480 (2002). (Pubitemid 34308489)
120. Fukui H, Murakami M, Yoshikawa H, Takada K, Muranishi S. Studies on the promoting effect of lipid-surfactant mixed micelles (MM) on intestinal absorption of colloidal particles. Dependence on particle size and administration site. J. Pharmacobiodyn. 10(6), 236-242 (1987)
121. Graf A, Rades T, Hook SM. Oral insulin delivery using nanoparticles based on microemulsions with different structure-types: optimisation and in vivo evaluation. Eur. J. Pharm. Sci. 37(1), 53-61 (2009).
122. Elsayed A, Remawi MA, Qinna N, Farouk A, Badwan A. Formulation and characterization of an oily-based system for oral delivery of insulin. Eur. J. Pharm. Biopharm. 73(2), 269-279 (2009).
123. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1(6), 457-462 (2002). (Pubitemid 37361488)
124. Morishita M, Morishita I, Takayama K, Machida Y, Nagai T. Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol. Pharm. Bull. 16(1), 68-72 (1993). (Pubitemid 23121752)
125. Cilek A, Celebi N, Tirnaksiz F, Tay A. A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats. Int. J. Pharm. 298(1), 176-185 (2005). (Pubitemid 40828338)
126. Fagerholm U, Sjostrom B, Sroka-Markovic J, Wijk A, Svensson M, Lennernas H. The effect of a drug-delivery system consisting of soybean phosphatidyl choline and medium-chain monoacylglycerol on the intestinal permeability of hexarelin in the rat. The J. Pharm. Pharmacol. 50(5), 467-473 (1998). (Pubitemid 28241132)
127. Aungst BJ, Saitoh H, Burcham DL, Huang S-M, Mousa SA, Hussain MA. Enhancement of the intestinal absorption of peptides and nonpeptides. J. Control. Release 41(1-2), 19-31 (1996). (Pubitemid 26246360)
128. Hastewell J, Lynch S, Williamson I, Fox R, Mackay M. Absorption of human calcitonin across the rat colon in vivo. Clin. Sci. 82(5), 589-594 (1992).
129. New R, Littlewood G, Guard P, Browning I, Hotten P. Intestinal delivery of calcitonin in pig. Int. J. Pharm. 156(1), 1-8 (1997). (Pubitemid 27400074)
130. Yoshiura H, Tahara Y, Hashida M et al. Design and in vivo evaluation of solid-in-oil suspension for oral delivery of human growth hormone. Biochem. Eng. J. 41(2), 106-110 (2008).